The IMPACT (Immediate Preoperative Anastrazole, Tamoxifen, or combined with Tamoxifen) trial is one of the first studies to show early molecular changes in ER+ breast cancer after a brief exposure to hormonal treatment. This evidence concerns the gene ESR1 and breast carcinoma.